PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.50%
EBIT growth above 1.5x CRVO's 5.75%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
16.24%
Operating income growth under 50% of CRVO's 37.37%. Michael Burry would be concerned about deeper cost or sales issues.
12.65%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
12.55%
EPS growth of 12.55% while CRVO is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
12.55%
Diluted EPS growth of 12.55% while CRVO is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-72.30%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-72.30%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-364.91%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-364.91%
Negative 5Y OCF/share CAGR while CRVO is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-364.91%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-5621.33%
Negative 10Y net income/share CAGR while CRVO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-5621.33%
Negative 5Y net income/share CAGR while CRVO is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-5621.33%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-1604.85%
Negative equity/share CAGR over 10 years while CRVO stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-1604.85%
Negative 5Y equity/share growth while CRVO is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-1604.85%
Negative 3Y equity/share growth while CRVO is at 57472.71%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-43.54%
Negative asset growth while CRVO invests at 28.31%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-8.62%
We have a declining book value while CRVO shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
6.57%
Debt shrinking faster vs. CRVO's 179.78%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
No Data
No Data available this quarter, please select a different quarter.
-21.27%
We cut SG&A while CRVO invests at 90.46%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.